Nektar Therapeutics (NKTR.OQ)
24 Mar 2017
Nektar Therapeutics said its experimental opioid, designed to achieve pain relief without the euphoria that can lead to abuse and addiction, succeeded in a key late-stage study.
* Co to discuss next steps with FDA, looks for strategic partner
March 20 Nektar Therapeutics said its experimental opioid, designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study.
* Nektar Therapeutics reports fourth quarter and year-end 2016 financial results
BRIEF-Nektar Therapeutics presents new clinical data from ongoing phase 1 dose-escalation study of NKTR-214
* Nektar Therapeutics presents new clinical data from ongoing phase 1 dose-escalation study of NKTR-214 at the society for immunotherapy of cancer (SITC) 2016 annual meeting
* Nektar Therapeutics reports financial results for the third quarter of 2016
* Nektar therapeutics announces public offering of shares of common stock
Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.
* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214
|Takeda Pharmaceutical Co Ltd (4502.T)||¥5,195||-67.00|
|Eisai Co., Ltd (4523.T)||¥5,928||-114.00|
|NOF CORPORATION (4403.T)||¥1,174||-16.00|
|Dr.Reddy's Laboratories Ltd (REDY.NS)||Rs2,642.20||+13.85|
|Novo Nordisk A/S (NOVOb.CO)||kr.231.80||+0.20|
|Pfizer Inc. (PFE.N)||$34.00||-0.29|
|Novartis AG (NOVN.S)||CHF73.15||-0.60|
|Roche Holding Ltd. (ROG.S)||CHF250.90||-2.00|
|Roche Holding Ltd. (RO.S)||CHF251.25||-1.25|
|GlaxoSmithKline plc (GSK.L)||1,662.50||-8.00|